Post by
MrMugsy on Jun 17, 2022 10:34am
Commercial Study ... expected in Q2
Into the final turn in calendar Q2.
Would really like to see what this study is saying about our peak revenue potential with OTENA. Will see if the report writers know their stuff.
1. $25B market size (for now)
2. IP of 20 years (declining)
3. opportunity to be "product of choice" after waking up in OR
4. amazing safety profile as compared to NSAIDs
5. non-addictive as compared to opioids.
Let's hope the stars are aligned on this one !!!